Life Sciences

  • May 28, 2026

    J&J Unit Cleared In Blood Pump Patent Suit In Mass.

    A Massachusetts federal jury on Thursday cleared a Johnson & Johnson MedTech subsidiary of allegations that it infringed a blood pump patent owned by a unit of Swedish medical device company Getinge AB.

  • May 28, 2026

    Chancery Tosses Insider Financing Suit Against Ayala Brass

    The Delaware Chancery Court has dismissed a stockholder derivative suit against several venture capital investors and directors of biotechnology company Ayala Pharmaceuticals Inc., ruling that the plaintiff failed to show the board could not independently evaluate litigation over a disputed 2023 financing deal.

  • May 28, 2026

    Abbott Labs Settles Ill. Genetic Privacy Suit

    Abbott Laboratories has inked a settlement with a proposed class of workers alleging the company's onboarding materials asked for employees' medical history in violation of an Illinois law aimed at protecting residents' genetic information, prompting an Illinois federal judge to dismiss the case Thursday.

  • May 28, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Tennessee became the latest state to approve a policy paving the way for more research into ibogaine; Vermont lawmakers brought a bill doubling cannabis potency and possession limits closer to the finish line; and California legislators approved a bill banning the sale of "laughing gas" used for recreational purposes. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • May 28, 2026

    Husch Blackwell Adds Manatt Healthcare Duo In LA

    Husch Blackwell LLP announced that a pair of Los Angeles-based commercial litigators from Manatt Phelps & Phillips LLP have joined the firm as part of its focus on expanding its California healthcare capabilities.

  • May 28, 2026

    Ex-Reebok CEO Says Biotech Investor Suit Was Shakedown

    Former Reebok CEO and billionaire philanthropist Paul Fireman said a "baseless" shareholder lawsuit against him and a biotech company he later sold to Janssen Pharmaceuticals Inc. for $85 million was an effort to get him to "cave" to demands for more money, according to a complaint filed in Massachusetts state court Wednesday.

  • May 28, 2026

    9th Circ. Won't Revisit FCA Ruling Over Drug Price Program

    The Ninth Circuit has said it will not disturb its March ruling allowing a hospital chain to pursue a False Claims Act lawsuit against various pharmaceutical companies for allegedly causing the government to overpay for drugs under a discount program.

  • May 28, 2026

    Split Fed. Circ. Says $452M Trade Secret Case Was Untimely

    A split Federal Circuit panel on Thursday erased Insulet Corp.'s trade secret victory against EOFlow Co. Ltd., holding that the medical device maker filed its claims too late and reversing a $452 million jury verdict that was later reduced to $59.4 million.

  • May 27, 2026

    Pharmacies Beat Fla. Hospitals' Opioids Suit

    A Florida state judge has handed Walmart, Walgreens and CVS a win in a fight with hospitals over treatment of opioid-addicted patients, finding the hospitals cannot recover damages under state racketeering law because their injuries are indirect.

  • May 27, 2026

    Inovio Brass Hit With Suit Over FDA Approval Claims

    Executives and directors of Inovio Pharmaceuticals Inc. on Wednesday were slapped with a shareholder derivative suit accusing them of damaging the company with misleading statements regarding the likelihood that the U.S. Food and Drug Administration would grant priority review to its DNA medicine.

  • May 27, 2026

    3 Generic Drug Antitrust Deals Totaling $17.9M Get Final Nod

    A Connecticut federal judge on Wednesday gave final approval to a $17.9 million generic drug price-fixing settlement between pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc., and Lannett Co. Inc. and 48 states, territories, and governments, finding the terms reasonable despite an objection.

  • May 27, 2026

    ProPublica Denied Access To Ranbaxy Antitrust MDL Docs

    A Massachusetts federal court denied ProPublica's bid to unseal court filings in settled multidistrict litigation alleging a subsidiary of Indian drugmaker Sun Pharmaceuticals illegally delayed market entry of generic drugs, ruling the nonprofit news organization's request came too late in the case.

  • May 27, 2026

    Pharmacies Hit With Injunction In Gilead Counterfeit Drug Row

    A New York federal judge has issued a preliminary injunction blocking a pair of Queens pharmacies from selling any human immunodeficiency virus medications that bear the Gilead name or the name of two of its products.

  • May 27, 2026

    NJ Justices Revive Eye Injury Suit For 'Gatekeeping' Test

    The Supreme Court of New Jersey revived a woman's suit alleging she suffered serious eye injuries because of a defect in Allergan USA Inc.'s product Ozurdex, ruling Wednesday that the trial court failed to conduct the gatekeeping inquiry required when there is a dispute over the reliability of expert testimony.

  • May 27, 2026

    Stock Trade Co. Wants Out Of Mallinckrodt Clawback Suit

    A high-frequency stock trading firm is asking a Delaware bankruptcy judge to make it the latest defendant dismissed from a bid by Mallinckrodt PLC to recover $1.6 billion paid for stock buybacks before the opioid distributor's bankruptcy.

  • May 27, 2026

    Squires Institutes 3 IPRs, Refuses Case With Limited Impact

    U.S. Patent and Trademark Office Director John Squires granted three petitions for inter partes review in his newest bulk order and broke down why he previously rejected CyberSecure IPS LLC's challenge to a Network Integrity Systems Inc. optical fibers monitoring patent.

  • May 27, 2026

    Squires Says Sun PGR Petition Denied For Not Naming Parent

    Sun Pharmaceutical Industries Inc.'s failure to name its parent company in its challenge to a Biofrontera Inc. patent was why its request for review was rejected early, U.S. Patent and Trademark Office Director John Squires has said.

  • May 27, 2026

    Pierce Atwood Rips Billionaire's 'Absurd' Suit Over Asset Sale

    Pierce Atwood and two attorneys urged a Massachusetts federal judge to reject a Ukrainian billionaire's suit blaming them for a $1.8 million damages order in investor litigation over the billionaire's failed biotech company, saying his own wrongdoing led to the judgment.

  • May 26, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week handled a broad mix of cross-border corporate control disputes, merger settlements, startup equity fights, advancement claims and board oversight litigation, while also weighing fallout from high-profile deals involving Microsoft Corp., The Boeing Co. and Nikola Corp.

  • May 26, 2026

    9th Circ. Backs Reinstating DEI Grants Nixed By Trump

    The Ninth Circuit on Tuesday partially upheld a lower court's preliminary injunction and class certification orders in litigation from University of California researchers against President Donald Trump, backing the reinstatement of grants terminated due to presidential orders against diversity, equity and inclusion initiatives while reversing the injunction for those grants that were rescinded without explanation.

  • May 26, 2026

    Conn. Drug Price Law Still Allows Hikes, 2nd Circ. Told

    Wholesale distributors that abide by Connecticut's drug price cap law can hike the cost of their other products to ensure they don't suffer losses, the state told the Second Circuit Tuesday, raising the ire of the companies trying to invalidate the new statute.

  • May 26, 2026

    Beasley Allen Fails To Overturn J&J Talc Disqualification

    A New Jersey federal judge affirmed the Beasley Allen Law Firm's disqualification from multidistrict litigation over Johnson & Johnson's talcum powder on Tuesday, determining that the firm has failed to provide a valid reason to back its attempt at a stay and temporary reinstatement into the matter.

  • May 26, 2026

    Squires' Institution Flips Are Increasing Uncertainty At PTAB

    U.S. Patent and Trademark Office Director John Squires has created a record low institution rate at the Patent Trial and Appeal Board, and attorneys say it's becoming increasingly clear that even an initial approval from the director may not last.

  • May 26, 2026

    Eli Lilly Expands Vaccine Push With Deals Worth Up To $3.8B

    Eli Lilly and Co. said Tuesday it will buy three companies involved in vaccine development — Curevo Inc., LimmaTech Biologics AG, and Vaccine Company Inc. — for a total of up to roughly $3.83 billion.

  • May 22, 2026

    Law360 Reveals Titans Of The Plaintiffs Bar

    This past year, 10 lawyers across the country at plaintiffs' firms big and small helped secure millions of dollars in settlements and verdicts for their clients, going up against powerful defendants like Google, Monsanto and the Trump administration, earning the attorneys recognition as Law360's Titans of the Plaintiffs Bar for 2026.

Expert Analysis

  • How Food, Beverage Claims May Preview Cosmetic Litigation

    Author Photo

    Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.